Patent: RE39293
✉ Email this page to a colleague
Summary for Patent: RE39293
Title: | Separation of plasma components |
Abstract: | A method for separating components from plasma, the method comprising (I) separating the plasma into a first and second component, the first component comprising an albumin/.alpha.-1-antirypsin pool and the second component comprising plasma containing components having a molecular mass greater than albumin; (II) treating the second component to form an immunoglobulins concentrate containing immunoglobulins substantially free from components having a molecular mass less than immunoglobulins; (III) treating the immunoglobulins concentrate to remove components having a molecular mass greater than immunoglobulins; and (IV) separating albumin and .alpha.-1-antitrypsin from the albumin/.alpha.-1-antitrypsin pool. |
Inventor(s): | Gilbert; Andrew Mark (Lane Cove, AU), Conlan; Brendon (Binya, AU), Nair; Chenicheri Hariharam (Baulkham Hills, AU) |
Assignee: | Life Therapeutics Limited (Frenchs Forest, AU) |
Application Number: | 10/632,644 |
Patent Claims: | see list of patent claims |
Details for Patent RE39293
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Octapharma Pharmazeutika Produktionsges.m.b.h. | CUTAQUIG | immune globulin subcutaneous (human)-hipp | Solution | 125668 | 12/12/2018 | ⤷ Try a Trial | 2040-01-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |